{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:03:19Z","timestamp":1792713799920,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chimeric antigen receptor (CAR) T-cell therapy using brexucabtagene autoleucel (BA) induces remission in many patients with mantle cell lymphoma (MCL), and BA is the only CAR T-cell therapy approved by the FDA for MCL. However, development of relapses to BA is recognized with poor patient outcomes. Multiple CAR T-cell therapies have been approved for other lymphomas and the resistance mechanisms have been investigated. However, the mechanisms underlying BA relapse in MCL have not been investigated and whether any previously reported resistance mechanisms apply to BA-relapsed patients with MCL is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To interrogate BA resistance mechanisms in MCL, we performed single-cell RNA sequencing on 39 longitudinally collected samples from 15 BA-treated patients, and multiplex cytokine profiling on 80 serial samples from 20 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We demonstrate that after BA relapse, the proportion of T cells, especially cytotoxic T cells (CTLs), decreased among non-tumor cells, while the proportion of myeloid cells correspondingly increased. <jats:italic>TIGIT<\/jats:italic>, <jats:italic>LAG3<\/jats:italic>, and <jats:italic>CD96<\/jats:italic> were the predominant checkpoint molecules expressed on exhausted T cells and CTLs; only <jats:italic>TIGIT<\/jats:italic> was significantly increased after relapse. CTLs expanded during remission, and then contracted during relapse with upregulated <jats:italic>TIGIT<\/jats:italic> expression. Tumor cells also acquired TIGIT expression after relapse, leading to the enhanced interaction of tumor cell TIGIT with monocyte CD155\/PVR. In myeloid cells, post-relapse HLA-II expression was reduced relative to pretreatment and during remission. Myeloid-derived suppressor cells (MDSCs) were enriched after relapse with elevated expression of activation markers, including <jats:italic>CLU<\/jats:italic> (clusterin) and <jats:italic>VCAN<\/jats:italic> (versican). Extracellular chemokines (CCL4, CXCL9, CXCL13), soluble checkpoint inhibitors (sPD-L1, sTIM3, s4-1BB), and soluble receptors (sIL-2R, sTNFRII) were decreased during remission but elevated after relapse.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data demonstrate that multiple tumor-intrinsic and -extrinsic factors are associated with T-cell suppression and BA relapse. Among these, TIGIT appears to be the central player given its elevated expression after BA relapse in not only CTLs but also MCL cells. The acquisition of TIGIT expression on tumor cells is MCL-specific and has not been reported in other CAR T-treated diseases. Together, our data suggest that co-targeting TIGIT may prevent CAR T relapses and thus promote long-term progression-free survival in MCL patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12943-022-01655-0","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T12:03:03Z","timestamp":1664193783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Vivian Changying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingling","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enyu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangchun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"1655_CR1","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"1655_CR2","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1111\/bjh.17197","volume":"192","author":"P Jain","year":"2021","unstructured":"Jain P, Nastoupil L, Westin J, Lee HJ, Navsaria L, Steiner RE, et al. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy. Br J Haematol. 2021;192:e38\u201342.","journal-title":"Br J Haematol"},{"key":"1655_CR3","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell cymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1655_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"1655_CR5","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1182\/blood.2020007445","volume":"137","author":"MD Jain","year":"2021","unstructured":"Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021;137:2621\u201333.","journal-title":"Blood"},{"key":"1655_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 2020;10:552\u201367.","journal-title":"Cancer Discov"},{"key":"1655_CR7","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"key":"1655_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.coi.2021.02.010","volume":"69","author":"TR Berger","year":"2021","unstructured":"Berger TR, Maus MV. Mechanisms of response and resistance to CAR T cell therapies. Curr Opin Immunol. 2021;69:56\u201364.","journal-title":"Curr Opin Immunol"},{"key":"1655_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 2020;10:702\u201323.","journal-title":"Cancer Discov"},{"key":"1655_CR10","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664.","journal-title":"Front Immunol"},{"key":"1655_CR11","doi-asserted-by":"publisher","first-page":"eabd4344","DOI":"10.1126\/sciimmunol.abd4344","volume":"6","author":"M Boulch","year":"2021","unstructured":"Boulch M, Cazaux M, Loe-Mie Y, Thibaut R, Corre B, Lemaitre F, et al. A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity. Sci Immunol. 2021;6:eabd4344.","journal-title":"Sci Immunol"},{"key":"1655_CR12","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","volume":"26","author":"Q Deng","year":"2020","unstructured":"Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med. 2020;26:1878\u201387.","journal-title":"Nat Med"},{"key":"1655_CR13","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1158\/2159-8290.CD-20-1677","volume":"11","author":"GM Chen","year":"2021","unstructured":"Chen GM, Chen C, Das RK, Gao P, Chen CH, Bandyopadhyay S, et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 2021;11:2186\u201399.","journal-title":"Cancer Discov"},{"key":"1655_CR14","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh D, Wong RA, Gholamin S, Maker M, Aftabizadeh M, Yang X, et al. IFNgamma is critical for CAR T cell-mediated cyeloid activation and induction of endogenous immunity. Cancer Discov. 2021;11:2248\u201365.","journal-title":"Cancer Discov"},{"key":"1655_CR15","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, et al. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021;12:2877.","journal-title":"Nat Commun"},{"key":"1655_CR16","first-page":"507871","volume":"1","author":"RW Yuanxin Wang","year":"2019","unstructured":"Yuanxin Wang RW, Zhang S, Song S, Jiang C, Han G, Wang M, et al. iTALK: an R package to characterize and illustrate intercellular communication. BioRxiv. 2019;1:507871.","journal-title":"BioRxiv"},{"key":"1655_CR17","doi-asserted-by":"publisher","first-page":"14069","DOI":"10.1038\/s41598-020-70584-z","volume":"10","author":"HH Jung","year":"2020","unstructured":"Jung HH, Kim JY, Lim JE, Im YH. Cytokine profiling in serum-derived exosomes isolated by different methods. Sci Rep. 2020;10:14069.","journal-title":"Sci Rep"},{"key":"1655_CR18","doi-asserted-by":"publisher","first-page":"e002899","DOI":"10.1136\/jitc-2021-002899","volume":"9","author":"A Hazini","year":"2021","unstructured":"Hazini A, Fisher K, Seymour L. Deregulation of HLA-I in cancer and its central importance for immunotherapy. J Immunother Cancer. 2021;9:e002899.","journal-title":"J Immunother Cancer"},{"key":"1655_CR19","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.3892\/ol.2017.6784","volume":"14","author":"JA Rodriguez","year":"2017","unstructured":"Rodriguez JA. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation. Oncol Lett. 2017;14:4415\u201327.","journal-title":"Oncol Lett"},{"key":"1655_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"1655_CR21","doi-asserted-by":"publisher","first-page":"eaav5599","DOI":"10.1126\/scitranslmed.aav5599","volume":"11","author":"N Jain","year":"2019","unstructured":"Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, et al. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma. Sci Transl Med. 2019;11:eaav5599.","journal-title":"Sci Transl Med"},{"key":"1655_CR22","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1182\/blood.2019003880","volume":"135","author":"R De Smedt","year":"2020","unstructured":"De Smedt R, Morscio J, Reunes L, Roels J, Bardelli V, Lintermans B, et al. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma. Blood. 2020;135:1685\u201395.","journal-title":"Blood"},{"key":"1655_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fimmu.2019.00481","volume":"10","author":"I Teige","year":"2019","unstructured":"Teige I, Martensson L, Frendeus BL. Targeting the antibody checkpoints to enhance cancer immunotherapy-focus on fcgammaRIIB. Front Immunol. 2019;10:481.","journal-title":"Front Immunol"},{"key":"1655_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","volume":"1231","author":"N Mukaida","year":"2020","unstructured":"Mukaida N, Sasaki SI, Baba T. CCL4 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1231:23\u201332.","journal-title":"Adv Exp Med Biol"},{"key":"1655_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-3-030-36667-4_5","volume":"1231","author":"SY Neo","year":"2020","unstructured":"Neo SY, Lundqvist A. The multifaceted roles of CXCL9 within the tumor microenvironment. Adv Exp Med Biol. 2020;1231:45\u201351.","journal-title":"Adv Exp Med Biol"},{"key":"1655_CR26","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1038\/s41467-019-10369-9","volume":"10","author":"M Pascual-Garcia","year":"2019","unstructured":"Pascual-Garcia M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, et al. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8(+) T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019;10:2416.","journal-title":"Nat Commun"},{"key":"1655_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-030-62658-7_6","volume":"1302","author":"M Hussain","year":"2021","unstructured":"Hussain M, Liu J, Wang GZ, Zhou GB. CXCL13 signaling in the tumor microenvironment. Adv Exp Med Biol. 2021;1302:71\u201390.","journal-title":"Adv Exp Med Biol"},{"key":"1655_CR28","doi-asserted-by":"publisher","first-page":"14963","DOI":"10.1038\/s41598-019-46491-3","volume":"9","author":"AQ Ohandjo","year":"2019","unstructured":"Ohandjo AQ, Liu Z, Dammer EB, Dill CD, Griffen TL, Carey KM, et al. Transcriptome network analysis identifies CXCL13-CXCR5 signaling modules in the prostate tumor immune microenvironment. Sci Rep. 2019;9:14963.","journal-title":"Sci Rep"},{"key":"1655_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s40425-019-0810-y","volume":"7","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhang J, Tu H, Liang D, Chang DW, Ye Y, et al. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients. J Immunother Cancer. 2019;7:334.","journal-title":"J Immunother Cancer"},{"key":"1655_CR30","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/CMAR.S162478","volume":"10","author":"F Li","year":"2018","unstructured":"Li F, Li N, Sang J, Fan X, Deng H, Zhang X, et al. Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection. Cancer Manag Res. 2018;10:941\u201351.","journal-title":"Cancer Manag Res"},{"key":"1655_CR31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3389\/fonc.2019.01015","volume":"9","author":"P Buderath","year":"2019","unstructured":"Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, et al. Soluble programmed death receptor ligands sPD-L1 and sPD-L2 as liquid biopsy markers for prognosis and platinum response in epithelial ovarian cancer. Front Oncol. 2019;9:1015.","journal-title":"Front Oncol"},{"key":"1655_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/bjh.17502","volume":"194","author":"C Bodor","year":"2021","unstructured":"Bodor C, Kotmayer L, Laszlo T, Takacs F, Barna G, Kiss R, et al. Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukaemia during ibrutinib therapy. Br J Haematol. 2021;194:355\u201364.","journal-title":"Br J Haematol"},{"key":"1655_CR33","doi-asserted-by":"publisher","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","volume":"11","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:eaau1167.","journal-title":"Sci Transl Med"},{"key":"1655_CR34","first-page":"375","volume":"16","author":"PD Lulla","year":"2018","unstructured":"Lulla PD, Hill LC, Ramos CA, Heslop HE. The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018;16:375\u201386.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1655_CR35","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","volume":"12","author":"Z Jackson","year":"2022","unstructured":"Jackson Z, Hong CJ, Schauner R, Dropulic B, Caimi PF, de Lima M, et al. Sequential single-cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with non-Hodgkin lymphoma. Cancer Discovery. 2022;12:1886\u2013903.","journal-title":"Cancer Discovery"},{"key":"1655_CR36","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.3389\/fimmu.2018.02821","volume":"9","author":"XM Zhou","year":"2018","unstructured":"Zhou XM, Li WQ, Wu YH, Han L, Cao XG, Yang XM, et al. Intrinsic expression of immune checkpoint molecule TIGIT could help tumor growth in vivo by suppressing the function of NK and CD8(+) t cells. Front Immunol. 2018;9:2821.","journal-title":"Front Immunol"},{"key":"1655_CR37","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fonc.2020.00188","volume":"10","author":"J Zhou","year":"2020","unstructured":"Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020;10:188.","journal-title":"Front Oncol"},{"key":"1655_CR38","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.3390\/jcm10132872","volume":"10","author":"C Vanhaver","year":"2021","unstructured":"Vanhaver C, van der Bruggen P, Bruger AM. MDSC in mice and men: mechanisms of immunosuppression in cancer. J Clin Med. 2021;10:2872.","journal-title":"J Clin Med"},{"key":"1655_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104302","volume":"362","author":"MD Sanchez-Pino","year":"2021","unstructured":"Sanchez-Pino MD, Dean MJ, Ochoa AC. Myeloid-derived suppressor cells (MDSC): when good intentions go awry. Cell Immunol. 2021;362:104302.","journal-title":"Cell Immunol"},{"key":"1655_CR40","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. MDSC: markers, development, states, and unaddressed complexity. Immunity. 2021;54:875\u201384.","journal-title":"Immunity"},{"key":"1655_CR41","doi-asserted-by":"publisher","first-page":"29521","DOI":"10.1038\/srep29521","volume":"6","author":"JM Zhou","year":"2016","unstructured":"Zhou JM, Donatelli SS, Gilvary DL, Tejera MM, Eksioglu EA, Chen XH, et al. Therapeutic targeting of myeloid-derived suppressor cells involves a novel mechanism mediated by clusterin. Sci Rep. 2016;6:29521.","journal-title":"Sci Rep"},{"key":"1655_CR42","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1158\/0008-5472.CAN-11-2905","volume":"72","author":"DC Gao","year":"2012","unstructured":"Gao DC, Joshi N, Choi HJ, Ryu SH, Hahn M, Catena R, et al. Myeloid progenitor cells in the Premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012;72:1384\u201394.","journal-title":"Cancer Res"},{"key":"1655_CR43","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/cells9081785","volume":"9","author":"YJ Cha","year":"2020","unstructured":"Cha YJ, Koo JS. Role of tumor-associated myeloid cells in breast cancer. Cells. 2020;9:1785.","journal-title":"Cells"},{"key":"1655_CR44","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1469594","volume":"7","author":"L Wang","year":"2018","unstructured":"Wang L, Jia B, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, et al. VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. Oncoimmunology. 2018;7:e1469594.","journal-title":"Oncoimmunology"},{"key":"1655_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1158\/2326-6066.CIR-20-0433","volume":"9","author":"G Xin","year":"2021","unstructured":"Xin G, Chen Y, Topchyan P, Kasmani MY, Burns R, Volberding PJ, et al. Targeting PIM1-mediated metabolism in myeloid suppressor cells to treat cancer. Cancer Immunology Research. 2021;9:454\u201369.","journal-title":"Cancer Immunology Research"},{"key":"1655_CR46","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1158\/0008-5472.CAN-16-0839","volume":"76","author":"D Sarhan","year":"2016","unstructured":"Sarhan D, Cichocki F, Zhang B, Yingst A, Spellman SR, Cooley S, et al. Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells. Cancer Res. 2016;76:5696\u2013706.","journal-title":"Cancer Res"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01655-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-022-01655-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-022-01655-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T14:04:48Z","timestamp":1664201088000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-022-01655-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1655"],"URL":"https:\/\/doi.org\/10.1186\/s12943-022-01655-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]},"assertion":[{"value":"7 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patient specimens were collected with informed consent and approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.W. has received research support from Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genentech, Genmab, Innocare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal, Pharmacyclics, VelosBio and Vincerx.M.W. received a speaker honorarium from Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, BGICS, BioInvent, CAHON, Chinese Medical Association, Clinical Care Options, Dava Oncology, Eastern Virginia Medical School, Epizyme, Hebei Cancer Prevention Federation, Imedex, Janssen, Kite Pharma, Leukemia & Lymphoma Society, LLC TS Oncology, Medscape, Miltenyi Biomedicine GmbH, Moffit Cancer Center, Mumbai Hematology Group, Newbridge Pharmaceuticals, OMI, OncLive, Pharmacyclics, Physicians Education Resources (PER), Practice Point Communications (PPC), Scripps and The First Afflicted Hospital of Zhejiang University.M.W. is consultant to AstraZeneca, Bayer Healthcare, BeiGene, BioInvent, CSTone, DTRM Biopharma (Cayman) Limited, Epizyme, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Miltenyi Biomedicine GmbH, Oncternal, Pharmacyclics and VelosBio.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}